Researchers from the National Cancer Institute analyzed national healthcare survey data and cost resources data for breast, cervical, colorectal, lung, and prostate cancer screenings.
Screening for colon cancer represented approximately 64% of all total screening costs, with colonoscopy costs making up 55% of the total. Almost all of the cancer screening costs were attributed to private insurance (88.3%), with 8.5% attributed to Medicare and 3.2% attributed to Medicaid, uninsured patients or government programs, according to the study.
Limitations of the study include the self-reporting basis of the data, estimates not including follow-up costs after screening and variations of cost based on geographic location and providers.
“We screen for cancer because it works,” Karen Knudsen, PhD, CEO of the American Cancer Society, told The New York Times. “The cost is small compared to the cost of being diagnosed with late-stage disease.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
